Videos

Justine Kahn, MD, MS, discusses the Children’s Oncology Group study that identified a survival disparity among patients with de novo Hodgkin lymphoma of different races and economic statuses.

Kamran A. Ahmed, MD, gives an overview of the phase 1/2 study of radiation therapy followed by intrathecal trastuzumab and pertuzumab in the management of HER2-positive breast leptomeningeal disease.

Gilles Salles, MD, discusses the need for new therapies to treat diffuse large B-cell lymphoma.

Implications for using checkpoint inhibitors as neoadjuvant treatment for patients with advanced urothelial carcinoma based on clinical trial data.

Preferences for treating patients with locally advanced urothelial carcinoma based on various factors, including disease presentation and patient preference.

Elisa Agostinetto, MD, discusses the accuracy of PREDICT+, an online tool used to predict mortality in patients with early breast cancer patients and to aid in clinical decision making, to determine the survival of patients enrolled in the phase 3 ALTTO trial of adjuvant lapatinib with or without trastuzumab versus trastuzumab alone in patients with HER2+ early breast cancer. 

Loretta Nastoupil, MD, and John Burke, MD, discuss transplant as a treatment option for patients with relapsed/refractory [R/R] diffuse large B-cell lymphoma [DLBCL], as well as treatment options for patients with relapsed disease after transplant.

Loretta Nastoupil, MD, and John Burke, MD, provide insight into treating patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

Loretta Nastoupil, MD, and John Burke, MD, provide an overview of different prognostic factors that have been identified in diffuse large B-cell lymphoma (DLBCL).

John Mascarenhas, MD, and Ruben Mesa, MD, provide insight on the diagnosis and prognosis of myelofibrosis.

Loretta Nastoupil, MD, and John Burke, MD, discuss the therapeutic landscape for patients with transplant-ineligible, relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and begin with an overview of the disease.

Marcin Kortylewski, PhD, discusses the need for additional strategies for the treatment of acute myeloid leukemia.

Haris Ali, MD, discusses the use of ruxolitinib as peri-transplant treatment for patients with myelofibrosis.

Dr Perry Cook discusses the challenges of treating relapsed/refractory follicular lymphoma in later lines and describes ongoing developments in the treatment landscape.

A hematologist/oncologist provides insights on individualizing second-line therapy for patients with relapsed/refractory follicular lymphoma.

Perry Cook, MD, reviews the role of molecular testing and biomarkers in treatment selection in patients with follicular lymphoma.

A hematologist/oncologist discusses the tazemetostat as a treatment option for patients with relapsed/refractory follicular lymphoma.

A key opinion leader explains the first-line treatment options for follicular lymphoma and the challenges of treating patients with early disease progression.

Perry Cook, MD, presents the case of a 76-year-old man with relapsed/refractory follicular lymphoma.

A key opinion leader shares clinical practice pearls for the treatment of patients with unresectable HCC. 

Pierre Gholam, MD, discusses future directions and novel therapeutic agents for the treatment of unresectable HCC.

Gastroenterology expert, Dr Pierre Gholam, discusses the efficacy and safety data from the phase 3 IMbrave150 trial.

The doctors discuss new discoveries that may lead to a cure for MPNs.

Dr Gholam reviews the study design and key data from the phase 3 REFLECT trial.

The experts describe a new drug under review by the FDA that offers an option for patients with MPNs and low platelets and discuss what they are looking forward to in the next 3-5 years.

The doctors discuss withdrawing patients with MPNs from a JAK inhibitor, titration, and rechallenging.

An expert in the treatment of HCC comments on first-line therapeutic options for patients with previously untreated, advanced HCC.

Combination trials and new agents for MPNs, such as parsaclisib and momelotinib, are discussed in the context of recent ASCO presentations.

Dr Gholam, MD, provides expert analysis on the prognosis and treatment of a patient with unresectable HCC.

Alternative dosing schedules and the use of JAK inhibitors for patients with MPNs in the second-line setting are explored.